| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
62.68(B) |
| Last
Volume: |
1,679,486 |
Avg
Vol: |
759,365 |
| 52
Week Range: |
$546.39 - $1201.76 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 963 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 4 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
1,000 |
229,375 |
349,826 |
| Total Sell Value |
$0 |
$844,610 |
$230,924,183 |
$337,853,105 |
| Total People Sold |
0 |
1 |
12 |
17 |
| Total Sell Transactions |
0 |
1 |
34 |
88 |
| End Date |
2025-01-30 |
2024-10-29 |
2024-04-30 |
2023-05-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldstein Joseph L |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
6,548 |
|
- |
|
| Thompson Craig B. |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
620 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
448 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
2,352 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
1,548 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
1,548 |
|
- |
|
| Guarini Kathryn |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
448 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
1,548 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
17,748 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
1,559 |
|
- |
|
| Sing George L |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
166 |
27,828 |
|
- |
|
| Sing George L |
Director |
– • – |
2024-12-31 |
4 |
D |
$708.19 |
$1,379,554 |
D/D |
(1,948) |
27,662 |
|
- |
|
| Sing George L |
Director |
– • – |
2024-12-31 |
4 |
OE |
$413.33 |
$1,379,696 |
D/D |
3,338 |
29,610 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2024-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14 |
2,186 |
|
- |
|
| Fenimore Christopher R. |
SVP Finance & CFO |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$358,828 |
D/D |
(491) |
16,265 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$513,029 |
D/D |
(702) |
30,075 |
|
- |
|
| Pitofsky Jason |
VP Controller |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$217,781 |
D/D |
(298) |
4,664 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$708,155 |
D/D |
(969) |
34,792 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$770,274 |
D/D |
(1,054) |
49,074 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$222,166 |
D/D |
(304) |
48,829 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2024-12-16 |
4 |
D |
$730.81 |
$554,685 |
D/D |
(759) |
14,230 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2024-12-09 |
4 |
D |
$787.00 |
$215,638 |
D/D |
(274) |
14,989 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2024-12-09 |
4 |
D |
$787.00 |
$387,204 |
D/D |
(492) |
35,761 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2024-12-09 |
4 |
D |
$787.00 |
$387,204 |
D/D |
(492) |
30,777 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2024-12-09 |
4 |
D |
$787.00 |
$387,204 |
D/D |
(492) |
50,128 |
|
- |
|
1309 Records found
|
|
Page 1 of 53 |
|
|
29.85 (5.25%) 
